Effect of Bromocriptine in rheumatoid arthritis
Not Applicable
- Conditions
- Rheumatoid arthritis.Other seropositive rheumatoid arthritis
- Registration Number
- IRCT138803232027N1
- Lead Sponsor
- School of Pharmacy of Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
moderate to severe RA and had been treated with disease modifying antirheumatic drugs (DEMARDs) included: Methotrexate, Hydroxychloroquine, Sulphasalazine, and prednisolone at least for 3 months and was not cured.
Exclusion criteria: end of the study, patient’s unwillingness
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of joints with morning stiffness. Timepoint: Before intervention and 3, 3.5, and 6.5 months after the intervention. Method of measurement: HAQ disability index, taking history and Questionnaire.;Severity of disease. Timepoint: Before intervention and 3, 3.5, and 6.5 months after the intervention. Method of measurement: HAQ disability index,taking history and Questionnaire.;The number of joints with tenderness. Timepoint: Before intervention and 3, 3.5, and 6.5 months after the intervention. Method of measurement: HAQ disability index,taking history and Questionnaire.
- Secondary Outcome Measures
Name Time Method Serum prolactin level. Timepoint: Before intervention and 3, 3.5, and 6.5 months after the intervention. Method of measurement: labaratory.;ESR. Timepoint: Before intervention and 3, 3.5, and 6.5 months after the intervention. Method of measurement: Labaratory.